Bristol-Myers Squibb Company vs AbbVie Inc.
A head-to-head of Bristol-Myers Squibb Company (BMY) and AbbVie Inc. (ABBV) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | BMY | ABBV |
|---|---|---|
| Market Cap | $124.04B | $449.63B |
| P/E (TTM) | 17.06 | 125.36 |
| Forward P/E | 9.80 | 15.63 |
| P/S | 2.50 | 5.66 |
| P/B | 8.83 | -57.26 |
| EV/EBITDA | 8.29 | 24.76 |
| Dividend Yield | 2.86% | 2.52% |
| Profit Margin | 15.01% | 5.79% |
| Gross Margin | 71.08% | 70.24% |
| Operating Margin | 28.48% | 32.85% |
| Revenue Growth (YoY) | +2.57% | +12.43% |
| FCF Yield | 9.81% | 5.62% |
| Debt / Equity | 221.17 | — |
| Current Ratio | 1.42 | 0.80 |
Which is better: Bristol-Myers Squibb Company or AbbVie Inc.?
- ✓Larger by market cap: AbbVie Inc.
- ✓Cheaper valuation (lower P/E): Bristol-Myers Squibb Company
- ✓Higher dividend yield: Bristol-Myers Squibb Company
- ✓More profitable (net margin): Bristol-Myers Squibb Company
- ✓Faster revenue growth: AbbVie Inc.
- ✓Higher free-cash-flow yield: Bristol-Myers Squibb Company
Across 11 available metrics, Bristol-Myers Squibb Company leads 9–2.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.